Real-World Survival Outcomes Following Chemoradiotherapy with or Without Durvalumab in PD-L1-Defined Subgroups of Stage III Unresectable NSCLC

Janne Selke, Yvonne Dzierma, Katrin Manda, Guido Hildebrandt, Bernd Frerker, Paul Kalata, Christin Ackermann, Felix Bock · 2026

Read Real-World Survival Outcomes Following Chemoradiotherapy with or Without Durvalumab in PD-L1-Defined Subgroups of Stage III Unresectable NSCLC by Janne Selke, Yvonne Dzierma, Katrin Manda, Guido Hildebrandt, Bernd Frerker, Paul Kalata, Christin Ackermann, Felix Bock (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13297644.txt.

Description

Routine practice backs consolidation immunotherapy after chemoradiation for advanced lung cancer, at least when tumors express PD-L1. Janne Selke and colleagues present real-world survival data in 2026 for people with unresectable stage III non-small cell lung cancer, comparing outcomes with and without durvalumab.

Patients whose tumors were PD-L1 positive and who received durvalumab lived significantly longer, both overall and without progression, than comparable patients treated without it. PD-L1-positive patients who never got the drug fared worst of all. The authors read the pattern as support for the treatment's value outside trials, and as a reminder that PD-L1 testing and actual access to consolidation therapy shape survival.

Catalog record

CREATORJanne Selke, Yvonne Dzierma, Katrin Manda, Guido Hildebrandt, Bernd Frerker, Paul Kalata, Christin Ackermann, Felix Bock
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE29455
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13297644

Browse the full library · About the Tower of Babel